US 11,993,583 B2
Therapeutic compounds
Michael Graupe, Pacifica, CA (US); John O. Link, San Francisco, CA (US); Roland D. Saito, San Mateo, CA (US); Scott D. Schroeder, Union City, CA (US); Dimitrios Stefanidis, Saratoga, CA (US); Winston C. Tse, Redwood City, CA (US); and Jennifer R. Zhang, Union City, CA (US)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Nov. 25, 2019, as Appl. No. 16/694,332.
Application 16/694,332 is a division of application No. 16/016,718, filed on Jun. 25, 2018, granted, now 10,654,827.
Application 16/016,718 is a division of application No. 15/680,041, filed on Aug. 17, 2017, granted, now 10,071,985, issued on Sep. 11, 2018.
Claims priority of provisional application 62/457,555, filed on Feb. 10, 2017.
Claims priority of provisional application 62/377,312, filed on Aug. 19, 2016.
Prior Publication US 2020/0262815 A1, Aug. 20, 2020
Int. Cl. C07D 487/00 (2006.01); A61K 31/4439 (2006.01); A61K 31/537 (2006.01); A61K 31/675 (2006.01); A61K 31/7076 (2006.01); A61K 45/06 (2006.01); C07C 317/08 (2006.01); C07D 231/54 (2006.01); C07D 231/56 (2006.01); C07D 401/14 (2006.01); C07F 5/02 (2006.01)
CPC C07D 401/14 (2013.01) [A61K 31/4439 (2013.01); A61K 31/537 (2013.01); A61K 31/675 (2013.01); A61K 31/7076 (2013.01); A61K 45/06 (2013.01); C07C 317/08 (2013.01); C07D 231/54 (2013.01); C07F 5/025 (2013.01)] 3 Claims
OG exemplary drawing
 
1. A compound selected from the group consisting of:

OG Complex Work Unit Chemistry